Repositorio Dspace

HLA-A*03 may confer protection against long COVID through an enhanced immune response

Mostrar el registro sencillo del ítem

dc.contributor.author Pons-Fuster, Eduardo
dc.contributor.author Martínez-Rodríguez, Rodrigo
dc.contributor.author Gimeno-Arias, Lourdes
dc.contributor.author Alcaraz, M-J
dc.contributor.author Moreno, Marta
dc.contributor.author Gómez, José-M
dc.contributor.author Peláez-Ballesta, Ana-Isabel
dc.contributor.author García, Elisa
dc.contributor.author Tomas, Cristina
dc.contributor.author Muñoz, Ángeles
dc.contributor.author V
dc.contributor.author Ruiz-Lorente, Inmaculada
dc.contributor.author Ceballos, Diana
dc.contributor.author Minguela-Puras, Alfredo
dc.contributor.author Bernal-Morell, Enrique
dc.date.accessioned 2026-03-10T11:49:10Z
dc.date.available 2026-03-10T11:49:10Z
dc.date.issued 2025-06
dc.identifier.citation Pons-Fuster E, Martinez-Rodriguez R, Gimeno-Arias L, Alcaraz MJ, Moreno M, Gómez JM, et al. HLA-A*03 may confer protection against long COVID through an enhanced immune response. Infectious Diseases Now. junio de 2025;55(4):105057. doi:10.1016/j.idnow.2025.105057
dc.identifier.issn 2666-9927
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/25214
dc.description.abstract BACKGROUND: The COVID-19 pandemic has led to widespread infection, with a significant subset of patients developing persistent symptoms known as Long COVID. Understanding the genetic factors influencing Long COVID susceptibility and severity is crucial for development of targeted interventions. OBJECTIVE: This study aimed to evaluate the impact of HLA alleles, KIR receptors, and their interactions on the development of Long COVID in patients from southeastern Spain having contracted COVID-19 during the early 2020 pandemic wave. METHODS: A cross-sectional prospective study enrolled 153 COVID-19 patients. Three months post-infection, HLA-A, -B, -C, KIR genotyping and immunological variables were analyzed using serum and blood samples. Long COVID was diagnosed three years post- infection based on persistent symptoms. RESULTS: Among the participants, 71 developed Long COVID. HLA-A03 was less frequent in Long COVID compared to non-Long COVID patients (10.7 % vs. 30.5 %, p = 0.001). Patients with HLA-A03 had a higher percentage of CD8(+) T cells than patients with other allotypes (33.6 ± 13.4 % vs 28.7 ± 10.8 %, p = 0.033) and showed lower expression of KIR2DL1(1265 ± 547 vs 1465 ± 414 MFI, p = 0.031) and KIR3DL1 (300.6 ± 125.0 vs 398.9 ± 131.0 MFI, p = 0.047). Moreover, NK cells in HLA-A03 patients showed lower expression of the TIGIT inhibitory receptor (73.7 ± 12.2 % vs 78.2 ± 10.8 %, p = 0.046). CONCLUSION: HLA-A03 may play a protective role against Long COVID, potentially through enhanced immune responses involving CD8(+) T cells and NK cells. Further research in larger, diverse cohorts is needed to validate these findings and to refine personalized medicine strategies for managing COVID-19 sequelae.
dc.language.iso eng
dc.publisher ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
dc.rights Atribución/Reconocimiento 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by/4.0/deed.es
dc.subject.mesh Humans
dc.subject.mesh COVID-19/immunology/genetics
dc.subject.mesh Male
dc.subject.mesh Female
dc.subject.mesh Middle Aged
dc.subject.mesh Cross-Sectional Studies
dc.subject.mesh Prospective Studies
dc.subject.mesh SARS-CoV-2/immunology
dc.subject.mesh Aged
dc.subject.mesh Adult
dc.subject.mesh CD8-Positive T-Lymphocytes/immunology
dc.subject.mesh HLA-A3 Antigen/genetics/immunology
dc.subject.mesh Spain/epidemiology
dc.subject.mesh Receptors, KIR/genetics
dc.subject.mesh Killer Cells, Natural/immunology
dc.subject.mesh Alleles
dc.subject.mesh Genetic Predisposition to Disease
dc.subject.mesh Genotype
dc.title HLA-A*03 may confer protection against long COVID through an enhanced immune response
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 40107360
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S2666991925000363
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1016/j.idnow.2025.105057
dc.journal.title Infectious Diseases Now
dc.identifier.essn 2666-9919


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta